Headlines about KalVista Pharmaceuticals (NASDAQ:KALV) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. KalVista Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.4063891319295 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s rankings:
KalVista Pharmaceuticals (NASDAQ:KALV) opened at $10.02 on Thursday. The stock has a market capitalization of $108.06 and a PE ratio of -4.11. KalVista Pharmaceuticals has a fifty-two week low of $5.48 and a fifty-two week high of $15.80.
KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, December 14th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.05). KalVista Pharmaceuticals had a negative net margin of 1,379.58% and a negative return on equity of 70.20%. The company had revenue of $1.13 million during the quarter.
Several equities research analysts have weighed in on the company. ValuEngine raised KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday. BTIG Research raised their price target on KalVista Pharmaceuticals from $18.00 to $27.00 and gave the company a “buy” rating in a report on Monday, October 16th.
In other KalVista Pharmaceuticals news, Director Rajeev M. Shah acquired 850,000 shares of the firm’s stock in a transaction on Thursday, October 12th. The stock was purchased at an average cost of $8.50 per share, for a total transaction of $7,225,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Holdings A/S Novo sold 2,725,283 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $9.64, for a total value of $26,271,728.12. The disclosure for this sale can be found here. Company insiders own 49.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/04/kalvista-pharmaceuticals-kalv-getting-somewhat-positive-media-coverage-report-shows.html.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.